RNAi Therapeutics Market 2nd Edition 2019-2030

Abstract

The project titled, “RNAi Therapeutics Market (2nd Edition), 2019-2030” provides an extensive study of the rapidly growing market of RNAi Therapeutics and provides an outlook of the growing pipeline of RNAi therapeutics. RNAi therapeutic market have been one of the most actively evolving market, with its single drug “Onpattro” in market. RNAi therapeutic market is still in its developing stage. It is the regulatory mechanism that cells use to silence or inhibit gene expression through destruction of specific mRNA molecules. RNAi enable the sequence specific knockdown of target gene. This therapyis anticipated to emerge as viable alternative to conventional treatment option for indications such as age-relatedmacular degeneration (AMD), hepatitis C and various forms of cancer. The scope of this project primarily includes various RNAi based drugs targeting several therapeutic areas such as oncology, genetic disorders and infectious diseases. Several players, including RNAi therapeutic developers, research institutes, contract manufacturing organizations, and government organizations, are playing a critical role in the development and manufacturing of these therapeutics.